Many small cell lung cancer patients rapidly relapse due to the aggressive nature of the disease. While the current standard of care in the second-line setting can extend survival, treatment…
The Food and Drug Administration, the FDA, has granted capmatinib a “breakthrough therapy” designation as a first-line treatment for Non-Small Cell Lung Cancer (NSCLC) patients with MET mutation, EGFR Wild-type…
The main therapeutic objectives in treating metastatic disease are prolonging life (also called “Survival”) and Quality of Life (QoL), knowing the disease will stay in the body for life. ***…
Background The National Comprehensive Cancer Network, NCCN, is the health body which sets the world guidelines in treating cancer. The NCCN recommends clinical trials as the preferred option over current…
Don't miss opportunities to get drugs like this in a clinical trial setting! Why? Lurbinectedin monotherapy as a second-line therapy in patients with small cell lung cancer, SCLC, elicited a…
Background Bempegaldesleukin, NKTR-214, and nivolumab, Opdivo, was granted breakthrough deisgnation by the FDA for the first line treatment of patients with previously untreated unresectable or metastatic melanoma. Bempegaldesleukin, NKTR-214, is…
Background Pancreatic cancer is one of the most challenging types of cancer to treat, but new therapy using the body’s own immune system is providing new hope. Researchers at Baylor…
About Non Small Cell Lung Cancer, NSCLC Lung cancer is the leading cause of cancer death globally. Each year 1.76 million people die as a result of the disease; this…
Background - The first standard treatment for advanced ovarian cancer patients is platinum-based chemotherapy. If the patient responds to this chemotherapy, she will continue to receive it to the maximum…
Background - The combination of regorafenib (Stivarga) and nivolumab (Opdivo) will be compared with regorafenib alone in a phase III trial of patients with microsatellite stable (MSS) colorectal (CRC), cancer,…